A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2

By sjmartinez • February 27, 2024

Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, Davey RT Jr, Lye DC, Dodd LE, Yang OO, Benson CA, Deye GA, Doernberg SB, Hynes NA, Grossberg R, Wolfe CR, Nayak SU, Short WR, Voell J, Potter GE, Rapaka RR. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Ann Intern Med. 2024 Feb 27. doi: 10.7326/M23-2593. Epub ahead of print. PMID: 38408357.

Tags: Infectious Diseases, Publications

Related Posts

Access to HIV treatment during community-wide flooding: Experiences of people living with HIV and health care workers in Malawi, a mixed methods study

Mphande M, Paneno R, Robson I, Phiri K, Cornell M, van Oosterhout JJ, Eisenman DP, Njala J, Phiri S, Dovel K. Access to HIV treatment[...]

Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research

Gianella S, Lauring A, Paredes R, Croda J, Andes D, Uhlemann AC, Chew K, Stephenson KE, Lewnard JA, John ARO, Leung DT, Clancy CJ, Chu[...]

Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in Candida albicans

Zhou X, Hilk A, Solis NV, Scott N, Zajac C, Filler SG, Selmecki A. Recurrent mutations in the stress regulator Cap1 reveal a trade-off between[...]